A real-world study of immune checkpoint inhibitors in advanced triple-negative breast cancer.

Zheng ZhangYadi ZhangChuanling LiuJiakang ShaoYimeng ChenYimin ZhuLi ZhangBoyu QinZiqing KongXixi WangYutong WangDeqin HuangLiqun LiuYuxin ZhouRan TaoZengjie YangMei LiuWeihong Zhao

Published in: Cancer innovation (2023)

ICIs are effective in the treatment of advanced TNBC, and the adverse reactions are tolerable. A panel of biomarkers including LDH, ALP, and bNLR were identified to predict the efficacies of ICIs in TNBC treatment.

Keyphrases

drug induced